RankAlpha logo
Back to Rankings

CLYM

Climb BioD
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
View Chart
Current thesis
Primary company sources support a genuinely catalyst-rich 2026: subcutaneous budoprutug data in H1 2026, initial CLYM116 healthy-volunteer data in mid-2026, and first budoprutug data from pMN, ITP, and SLE studies in H2 2026, while cash, cash equivalents, and marketable securities of $160.7 million at December 31, 2025 are expected to fund operations into 2028 [#PR-2026-03-05].
Posture
Defensive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +1.4.
What can break
Clinical readouts in 2026 could miss on efficacy, PK/PD translation, or tolerability.
Momentum
95
Value
41
Sentiment
16
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $8.50 · Bull $14.00 · Bear $5.00
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $20.93
Why
Momentum95 · Δ7d +1.4
Value41 · Δ7d -0.1
Sentiment16 · Δ7d +4.9
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Momentum · See technicals
Momentum
95
26% active weight
Current posture
7d trendImproving
Δ7d
+1.4
Δ21d
+1.5
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
0.0
Sentiment
16
34% active weight
Current posture
7d trendImproving
Δ7d
+4.9
Δ21d
+0.7
Why this grade

Composite grade D. Momentum 95.3 / Value 41.1 / Sentiment 16.1

Fundamentals (TTM)
As of 2026-07-17
Market Cap
$727.24M
Beta
-0.15
Shares Out
57.26M
P/E (TTM) · Derived
-14.4
P/S (TTM)
-
P/FCF (TTM) · Derived
-16.09
Rev YoY
-
EPS YoY
-34.7%
Gross Margin
-
Op Margin
-
Net Debt
-$100.54M
Current Ratio
27.86
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology